An interventional study of 2D ultrasound and SonoAVC in Infertility, sponsored by Eugonia. Status unknown at 1 site in Greece. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-08.
Sponsored by Eugonia · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Infertility by Eugonia — none open to participants now, none under way, none of them phase 3. Infertility · Eugonia.
Among the 13 studies in Infertility by Eugonia, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2018, is one of 5 with no phase, and was the 11th registered.
2,090 studies on the registry are indexed under Infertility; 356 are open to participants now.
Browse Infertility studies →None of the 13 studies in Infertility by Eugonia is open now. The open studies under Infertility, anywhere →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 40 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2018.
This study's enrollment of 52 is below the median of 134 across 1,415 interventional studies indexed under Infertility.
Median enrollment 84 across the 10 interventional studies, 60 across the 3 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eugonia is the lead sponsor of 16 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Infertility by Eugonia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Accurate follicular monitoring of Controlled Ovarian Stimulation by transvaginal ultrasound is considered important for the success of human in vitro fertilization (IVF). The aim of this study is to evaluate the effect of timing oocyte maturation and egg collection on the basis of follicular measurements made automatically with Sono Automated Volume Calculation (SonoAVC) against those made with conventional 2D ultrasound in relation to the number of mature oocytes collected.
This study will take place in women undergoing IVF who are high responders (>=14 follicles>=11mm) and hence at risk for developing ovarian hyperstimulation syndrome (OHSS), treated with a GnRH antagonist protocol and administered GnRH agonist to trigger final oocyte maturation.
Accurate follicular monitoring of Controlled Ovarian Stimulation by transvaginal ultrasound is considered important for the success of human in vitro fertilization (IVF). Accurate assessment of the size of follicles is important for the timing of oocyte maturation and subsequent oocyte retrieval.
Serial assessment of follicle number and size is used routinely to assess the response to ovarian stimulation during assisted reproduction treatment (ART). Two-dimensional (2D) ultrasound is used to identify and scroll through each ovary while the observer quantifies the number of follicles present. An objective assessment of the size of the larger follicles, commonly those measuring >10 mm, is then made through a series of 2D measurements of their perceived mean diameter.
Sono Automated Volume Calculation (SonoAVC; GE Medical Systems) is a new software program that can be applied to datasets acquired with use of threedimensional (3D) ultrasound. It individually identifies and quantifies the size of any hypoechoic region within these 3D datasets, providing an automatic estimation of their absolute dimensions and volume. SonoAVC is an ideal and, potentially, a clinically important tool for the assessment and measurement of follicles during controlled ovarian stimulation because each hypoechoic area is individually color coded, thereby eliminating the possibility of measuring the same follicle more than once.
In women with high ovarian response to gonadotrophin stimulation, the accurate measurement of the number and size of follicles present in hyperstimulated ovaries is a challenge for clinicians and ultrasonographers.
The aim of this study is to evaluate the effect of timing final oocyte maturation trigger and egg collection on the basis of follicular measurements made automatically with SonoAVC against those made with conventional 2D ultrasound in relation to the number of mature oocytes collected. This study will include women undergoing ART who are high responders (presence of =>14 follicles>=11mm) and hence at risk for developing ovarian hyperstimulation syndrome (OHSS), treated with a GnRH antagonist protocol and are administered GnRH agonist to trigger final oocyte maturation. All resulting embryos (blastocysts) will be cryopreserved and transferred in a subsequent frozen cycle.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Two-dimensional (2D) ultrasound is used to identify number and size of ovarian follicles, to select optimal day for triggering final oocyte maturation.
Device: 2D ultrasound
SonoAVC is used to identify number and size of ovarian follicles, to select optimal day for triggering final oocyte maturation.
Device: SonoAVC
The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of conventional two-dimensional (2D) ultrasound.
The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of SonoAVC.
Number of mature oocytes
The number of mature (metaphase-II) oocytes retrieved
Time frame: Day of oocyte retrieval
Number of oocytes retrieved
Total number of oocytes retrieved
Time frame: Day of oocyte retrieval
Oocyte maturation rate
Percentage of mature oocytes/total number of oocytes
Time frame: Day of oocyte retrieval
Oocyte retrieval rate
Percentage of oocyte retrieved/number of follicles aspirated
Time frame: Day of oocyte retrieval
Number of fertilised oocytes
Number of fertilised oocytes displaying 2 pronuclei and 2 polar bodies
Time frame: 1 day post oocyte retrieval
Fertilisation rate
Percentage fertilised oocytes/oocytes inseminated
Time frame: 1 day post oocyte retrieval
Number of blastocysts
Number of embryos reaching the blastocyst stage
Time frame: 5 days post oocyte retrieval
Days of stimulation
Number of days recFSH is administered
Time frame: 10-15 days after menses
Total dose of recFSH
Total dose of recFSH administered during the ovarian stimulation period
Time frame: 10-15 days after menses
Ran from Aug 2018 to primary completion in Jan 2019, 5 months.
Of 386 non-industry interventional studies with no phase under Infertility, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 5 months is below that.
Counting every sponsor, half of 416 studies reached it within 24 months; a quarter within 10 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eugonia